Farewell regular flat white. 'Functional' coffees are hitting the high street

Functional coffees—mushroom blends (lion’s mane, reishi, chaga), protein, collagen, prebiotics and even CBD—are migrating from health-food niches onto mainstream high-street menus, with Starbucks, Black Sheep Coffee, Holland & Barrett and independents expanding ranges; Tastewise flags the category as a top 2026 trend and finds a 30% rise in UK menu listings over the past year. Retailers are monetising the shift with typical add-on prices of around £1 ($1–$2 in the US) and Black Sheep reports ~15% attach rates and unexpectedly strong demand for lion’s mane, suggesting a meaningful upsell and ARPU opportunity for chains. However, experts caution that clinical evidence is still limited, ingredient doses in commercial coffees vary and are often low, so health claims remain unproven—creating both a growth avenue and reputational/value-for-money risk for operators and investors.

Analysis

Functional coffees are migrating from health-food niches into mainstream high-street outlets, with examples in the article including Starbucks, Black Sheep Coffee, Holland & Barrett and independent shop Sipp; Tastewise flags the category as a top trend for 2026 and reports a 30% rise in mushroom coffees on UK menus over the past year. Operators are monetising the shift with add-on pricing typically around £0.99–£1.09 at Black Sheep and $1–$2 at Starbucks, and Black Sheep reports roughly 15% attach rates and anecdotally stronger-than-expected demand for lion's mane, implying a measurable ARPU uplift (the article calculates about £30/month if a customer upgrades daily). Consumer reception is heterogeneous: some habitual users report subjective benefits and pay repeatedly for collagen or mushroom shots, while many mainstream commuters are unfamiliar with the concept; the category therefore has early-adopter traction but uneven awareness. Scientific and clinical support is limited—nutrition and dietetics experts in the article note ingredient doses are often too low to replicate trial effects and that health claims remain unproven—creating upside via premium add-ons and differentiation but clear reputational and efficacy risk if regulatory scrutiny or negative evidence emerges.

Key Decisions for Investors

• Consider modest overweight exposure to large, well-capitalised coffee operators such as Starbucks (SBUX) that can scale add-on offerings and capture ARPU upside, while avoiding concentrated bets on small niche brands without distribution scale
• Monitor KPIs cited in the article—attach rates (Black Sheep ~15%), menu penetration (Tastewise 30% Y/Y for mushroom coffees) and ARPU uplift (roughly £30/month for daily upgrades)—and use sustained improvements in these metrics to increase conviction
• Maintain caution and position sizing given limited clinical evidence and variable ingredient quality; prioritise companies with clear labeling, quality control and conservative health claims to mitigate reputational/regulatory risk
• Prepare to trim or hedge positions if regulatory actions, consumer backlash or robust studies fail to support health claims, since the article highlights that benefits are unproven at typical commercial dosages